CN113994008A - 用于婴儿恶性骨硬化病的基因治疗载体 - Google Patents

用于婴儿恶性骨硬化病的基因治疗载体 Download PDF

Info

Publication number
CN113994008A
CN113994008A CN202080044921.1A CN202080044921A CN113994008A CN 113994008 A CN113994008 A CN 113994008A CN 202080044921 A CN202080044921 A CN 202080044921A CN 113994008 A CN113994008 A CN 113994008A
Authority
CN
China
Prior art keywords
seq
transfer plasmid
expression cassette
tcirg1
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044921.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·比尔德
D·里克斯
R·普拉巴卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spaceship Seven LLC
Original Assignee
Spaceship Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spaceship Seven LLC filed Critical Spaceship Seven LLC
Publication of CN113994008A publication Critical patent/CN113994008A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080044921.1A 2019-05-23 2020-05-22 用于婴儿恶性骨硬化病的基因治疗载体 Pending CN113994008A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852216P 2019-05-23 2019-05-23
US62/852,216 2019-05-23
PCT/US2020/034394 WO2020237219A1 (en) 2019-05-23 2020-05-22 Gene therapy vectors for infantile malignant osteopetrosis

Publications (1)

Publication Number Publication Date
CN113994008A true CN113994008A (zh) 2022-01-28

Family

ID=73458718

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044921.1A Pending CN113994008A (zh) 2019-05-23 2020-05-22 用于婴儿恶性骨硬化病的基因治疗载体

Country Status (12)

Country Link
US (1) US20220218844A1 (https=)
EP (1) EP3973066A4 (https=)
JP (2) JP7623299B2 (https=)
KR (1) KR20220012266A (https=)
CN (1) CN113994008A (https=)
AU (1) AU2020278046A1 (https=)
BR (1) BR112021023473A2 (https=)
CA (1) CA3137700A1 (https=)
IL (1) IL288193A (https=)
MX (1) MX2021014337A (https=)
SG (1) SG11202112347RA (https=)
WO (1) WO2020237219A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116042719A (zh) * 2022-12-28 2023-05-02 蓝图生物医药(广州)有限公司 一种重组腺相关病毒载体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055862T2 (hu) 2016-04-20 2021-12-28 Centro De Investig Energeticas Készítmények és eljárások PKLR fokozott génexpressziójára
SG11202002263TA (en) 2017-10-16 2020-04-29 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency
WO2019200167A1 (en) 2018-04-11 2019-10-17 Rocket Pharmaceuticals, Ltd. Compositions and methods for stem cell transplant
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176006A1 (en) * 2002-02-06 2005-08-11 Paolo Vezzoni Genetic markers for bone mass
WO2007124578A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
US20160175462A1 (en) * 2013-06-17 2016-06-23 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU2013309488A1 (en) * 2012-08-29 2015-03-05 Nature Technology Corporation DNA plasmids with improved expression
WO2014077863A1 (en) * 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
CN116064678A (zh) * 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
CN121102467A (zh) * 2016-04-22 2025-12-12 克莱格医学有限公司 用于细胞免疫疗法的组合物和方法
KR20240151726A (ko) 2016-09-08 2024-10-18 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. 판코니 빈혈 환자를 위한 유전자 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176006A1 (en) * 2002-02-06 2005-08-11 Paolo Vezzoni Genetic markers for bone mass
WO2007124578A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
US20160175462A1 (en) * 2013-06-17 2016-06-23 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOSCATELLI LLANA等: "Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis", 《HUMAN GENE THERAPY》, vol. 29, no. 8, 1 August 2018 (2018-08-01), pages 938 - 949, XP093054052, DOI: 10.1089/hum.2017.053 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116042719A (zh) * 2022-12-28 2023-05-02 蓝图生物医药(广州)有限公司 一种重组腺相关病毒载体及其应用

Also Published As

Publication number Publication date
EP3973066A1 (en) 2022-03-30
SG11202112347RA (en) 2021-12-30
MX2021014337A (es) 2022-03-17
EP3973066A4 (en) 2023-07-26
JP2025063200A (ja) 2025-04-15
WO2020237219A1 (en) 2020-11-26
KR20220012266A (ko) 2022-02-03
JP2022532802A (ja) 2022-07-19
CA3137700A1 (en) 2020-11-26
AU2020278046A1 (en) 2022-01-27
US20220218844A1 (en) 2022-07-14
JP7623299B2 (ja) 2025-01-28
IL288193A (en) 2022-01-01
BR112021023473A2 (pt) 2022-02-01

Similar Documents

Publication Publication Date Title
JP2025063200A (ja) 乳児性悪性大理石骨病に対する遺伝子療法ベクター
RU2650860C2 (ru) Векторы для экспрессии простатоассоциированных антигенов
AU2015263150B2 (en) Lentiviral vectors
AU2020260491B2 (en) Gene therapies for lysosomal disorders
CN111372943B (zh) 腺病毒及其用途
AU2018346104B2 (en) Gene therapies for lysosomal disorders
RU2758489C2 (ru) Композиции и способы для экспрессии нескольких биологически активных полипептидов с одного вектора для лечения заболеваний сердца и других патологий
CA2776272C (en) Development of a preventive vaccine for filovirus infection in primates
AU2020344628A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
AU2023265204A1 (en) Virus-derived construct plasmid library and construction of same
KR20220112283A (ko) Hunter 질환 치료용 아데노-연합된 바이러스 벡터
KR20080030956A (ko) 개선된 조절 발현 체계를 사용한 질병의 치료
KR20070114761A (ko) Ｓｉｖ­ｐｅｄｆ 벡터를 사용한 안조직 세포에 있어서의아포토시스 변성을 동반하는 질환의 치료제
TW202233830A (zh) 使用下一代工程化t細胞療法治療癌症之組合物及方法
CN101160139A (zh) 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物
HK1116092A (en) Remedy for disease associated with apoptotic degeneration in ocular cell tissue with the use of siv-pedf vector
HK1122837A (en) Treatment of disease using an improved regulated expression system

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220128

WD01 Invention patent application deemed withdrawn after publication